Infinity Pharmaceutical (INFI) Trading 'Nearly at Cash' Despite Drug that Works - Truist Securities
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $12.00 price target on Infinity Pharmaceutical (NASDAQ: INFI) after catching ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
